Perha Pharmaceuticals has discovered new pyrazolo[1,5-a]pyrimidine derivatives acting as adenosine A3 receptor antagonists potentially useful for the treatment of ulcerative colitis, atopic dermatitis, glaucoma, asthma, liver fibrosis, renal disorders, hearing loss and glioblastoma, among others.
Accutar Biotechnology Inc. has synthesized new protein-protein interaction targeted chimera (PPI-TAC) compound comprising an E3 ubiquitin ligase-binding moiety covalently bound to a phosphatidylinositol 3-kinase α (PI3Kα)-targeting moiety. They act as PI3Kα H1047R mutant degradation inducers potentially useful for the treatment of cancer.
Acute lung injury (ALI) is a severe inflammatory condition marked by disruption of the alveolar-capillary barrier and impaired gas exchange. Emerging evidence implicates cathepsin L as a key contributor to ALI pathogenesis through protease-mediated tissue damage and amplification of inflammatory responses. Researchers from Zhejiang University of Technology reported the development of a new cathepsin L inhibitor designed for the treatment of ALI.
Naturecell Co. Ltd.’s U.S. subsidiary, Naturecell America, has received IND clearance from the FDA for Astrostem-AU, an autologous adipose-derived mesenchymal stem cell therapy for adults with autism spectrum disorder (ASD).
U.S. researchers have published data regarding IVMT-Rx-4, a melanoma differentiation-associated gene-9 (MDA-9) inhibitor with potential to treat bone-metastatic prostate cancer.
CSPC Pharmaceutical Group Ltd.’s SYS-6051 has gained clinical trial clearance from China’s National Medical Products Administration (NMPA) for advanced solid tumors. SYS-6051 is a human tissue factor-targeted antibody-drug conjugate that binds to tissue factor expressed on the surface of tumor cells.
Mabwell (Shanghai) Bioscience Co. Ltd.’s has announced IND acceptance by China’s National Medical Products Administration (NMPA) for the company’s LILRB4/CD3 T-cell engager bispecific antibody 6MW5311. The drug candidate is being developed for hematologic malignancies, specifically acute myeloid leukemia (AML), chronic myelomonocytic leukemia and multiple myeloma.
Alethio Therapeutics Inc. has unveiled ATX-011, a mutation-agnostic antibody for essential thrombocythemia. ATX-011 is a potential first-in-class monoclonal antibody based on a new target identified on mutant stem cells that drive myeloproliferative neoplasm disease progression.
BMAL1 expression is tied to important cellular processes, including cell proliferation, migration, cell cycle and DNA damage repairing. There is increasing evidence that it regulates the expression of various oncogenes and tumor-suppressor genes in cancer cells. Researchers hypothesized that modulating BMAL1 expression could be a new therapeutic approach for treating cancer, such as triple-negative breast cancer (TNBC).
A new metasurface design strategy that replaces rigid order with “engineered disorder” could significantly increase how many optical functions can be integrated into a single ultra-thin device without increasing size or complexity, according to a study published in Nature Communications. The study challenges a longstanding assumption in optical engineering that highly ordered, periodic structures are required to precisely control light.
RSS
